December 2019

Robert F. Poirier, Jr. MD, on the Approval of Lefamulin for CABP

December 13, 2019

Medical World News

In August, the FDA approved lefamulin (Xenleta) for the treatment of CABP after results from 2 phase 3 studies showed that the novel antibiotic was noninferior to existing treatment options.

Two More Agents Bolster the Arsenal Against Gram-Negative Resistance

December 12, 2019

Multidrug-Resistant Infections

As the antibiotic pipeline produces new therapies, clinicians must understand each agent’s specific role in manage­ment of patients infected by multidrug-resistant pathogens.